[Skip to Navigation]
January 6, 2020

Paradigm Shift in Asthma Therapy for Adolescents: Should It Apply to Younger Children as Well?

Author Affiliations
  • 1Section of Allergy and Clinical Immunology, Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada
  • 2The Breathing Institute, Pulmonary Medicine Section, Children’s Hospital Colorado, Aurora
  • 3University of Colorado School of Medicine, Anschutz Medical Campus, Aurora
JAMA Pediatr. 2020;174(3):227-228. doi:10.1001/jamapediatrics.2019.5214

Asthma is one of the most common chronic conditions of childhood and is associated with significant effect on quality of life. An ongoing controversy remains how to best treat asthma in children and adolescents. A provocative evolution in this controversy is the publication of new recommendations by the Global Initiative for Asthma (GINA), which present a significant change in asthma therapy.1 Step 1 recommendations for mild asthma in adolescents 12 years and older and adults changed from as-needed short-acting β-agonist (SABA) to as-needed low-dose inhaled corticosteroid (ICS) formoterol (a long-acting β-agonist [LABA]). In children aged 6 to 11 years, GINA recommends that ICS therapy be used with SABA as needed or regular ICS with as-needed SABA as an alternative approach.

Add or change institution